Chandan Healthcare Limited — Investor Meet, 03-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Chandan Healthcare reported robust FY26 performance: Revenue grew 20.43% YoY, EBITDA surged 31.02% YoY to 20.25% margin, and PAT increased 22.04% YoY. The company is in aggressive expansion mode, securing 5 new PPP projects (estimated INR 800 Cr over 10 years) and entering metro markets. FY27 plans include launching 2 PET scans, UP's first genome lab, and scaling to 1,000 franchises in 24 months. Consolidated EBITDA (20.25%) is affected by the low-margin pharmacy segment and expansion costs, but standalone diagnostics deliver over 40% EBITDA. Management aims for 30-35% consolidated EBITDA, confident in future growth leveraging Tier 2/3 markets.